Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y Zevalin + BEAM + Rituximab in ASCT for Lymphoma
NCT01538472Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2003
- Primary completion
- Nov 2011
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in B-cell non-Hodgkin lymphoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Overall Survival Median at 5 years and 3-Year Overall Survival. Started Sep 2003; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT01538472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01538472.